Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06703645

Evaluation of Snakebite Cases in Assiut Governorate, Egypt (Prospective Study)

1. Study the sociodemographic profile of snakebite victims in Assiut Governorate. 2. Portray the clinical profile of snakebite victims admitted to Assiut University , El Eman General Hospital and Assiut General Hospital. 3. Assess the predictors of severity and outcome of cases.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Snake's envenomation is a serious socio-medical problem, which causes considerable mortality and morbidity, with approximately 125,000 deaths worldwide annually. There were 4.5 to 5.4 million bites every year, and of those figures, 40-50% had some clinical disability as a result. Furthermore, the death from such an issue could go somewhere between 80,000 and 130,000 individuals each year. In the Middle East and North Africa, there are over 70,000 snakebites bites each year.

There are many species of snakes, approximately 3,700 species of snakes worldwide only about 15% are venomous belong to the four large families including Viperidae, Colubridae, Elapidae and Atractaspidinae. Two of these toxic species are widespread in Egypt; the family Viperidae and the family Elapidae Egyptian copra Naja Haje.

Snake venoms are complex mixtures consisting of enzymatic components e.g., proteolytic enzymes e.g., serine protease and metalloproteases (SVMPs), non-enzymatic components e.g., cysteine-rich secretory proteins (CRISP), amines, lipids, nucleotides, and carbohydrates. Venoms also contain inorganic cations that are presumed to function as cofactors and include sodium, calcium, potassium, magnesium, and zinc.

Snake venoms are usually classified as hemotoxic or neurotoxic. Snakes of the Viperidae family have venom containing proteins that can disrupt the coagulation cascade, the hemostatic system and tissue integrity. In contrast, neurotoxic venoms, which are typical of the Elapidae snakes, contain several toxins that primarily affect the peripheral nervous system, in particular the neuromuscular junction.

Depending on the species of snakes, manifestations can be localized symptoms of mild pain, progressive edema, ecchymosis, and tissue necrosis and generalized ones as spontaneous bleeding e.g., bleeding per gums, epistaxis, hematuria, vaginal bleeding, hematemesis, hematochezia, hemoptysis, hemolytic anemia and hemolytic jaundice with hemototoxic snake venom. In severe cases patients may develop acute renal, myocardial infarction, disseminated intravascular coagulation, or even death. Ptosis, diplopia, dysphagia, trunk and limbs weakness, and respiratory paralysis which can lead to respiratory failure and apnea with neurotoxic snake venom.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients admitted with a reliable history of snakebite.
  • Presence of fang marks and/or signs of local and systemic envenomation.

Exclusion criteria

  • Fake or uncertain snakebites.
  • Patients with history of hematological disorders, liver diseases, renal diseases and anticoagulation therapy in the past week.
  • Patients who are not willing to participate in the study.

Treatment and study plan

Primary outcomes

  1. Number of Participants with recovery

    Time frame: through study completion, an average of 1 year".

    • Number of Participants with complete recovery.
    • Number of Participants with recovery with disability and complications as amputation and renal failure, etc.
  2. Number of Participants with Death

    Time frame: through study completion, an average of 1 year".

    Any complication due to snake bite end with death as respiratory arrest, disseminated intravascular coagulation and renal failure.

Study contacts

Contact information is provided by the study sponsor or research team.

Hala Mohammed Fathy, Professor

CONTACT

[email protected]

+20 1098038310

Rania Alkady Mohamed, demonstrator

CONTACT

[email protected]

01153387577

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Nov 25, 2024
Registry last updated
Nov 25, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.